Associated tags: Research, Matrix, Scientific Reports, Cell, Extracellular matrix, Pharmaceutical industry, Drug discovery, SAN, Electrophysiology, B cell, University, Health, Doctor of Philosophy, Vaccine
Locations: WASHINGTON, UNITED STATES, NORTH AMERICA, TEXAS
Human,
University,
Genetic engineering,
Heart failure,
Doctor of Philosophy,
Toxicity,
Research,
Cell,
RNA,
Cardiotoxicity,
Cardiac muscle,
Cryopreservation,
Scientific Reports,
Animal,
Electrophysiology,
SAN,
Extracellular matrix,
Drug discovery,
Arrhythmia,
B cell,
IPS,
Phenotype,
Genome,
Vaccine,
Pharmaceutical industry SAN ANTONIO, June 13, 2023 /PRNewswire/ -- StemBioSys, Inc. (StemBioSys) announced today the launch of CELLvo™ Atrial Cardiomyocyte, a "chamber specific" human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CM) designed to function identically to human atrial cardiomyocytes. StemBioSys developed CELLvo™ Atrial Cardiomyocyte to empower pharmaceutical companies and academics with a more precise, efficient and cost-effective platform for screening new drug products in vitro for cardiotoxicity compared to animal models and other in-vitro methods currently in use.
Key Points:
- StemBioSys developed CELLvo™ Atrial Cardiomyocyte to empower pharmaceutical companies and academics with a more precise, efficient and cost-effective platform for screening new drug products in vitro for cardiotoxicity compared to animal models and other in-vitro methods currently in use.
- "Having access to mature, human atrial cells derived from human induced pluripotent stem cells (hiPSCs) is a breakthrough in many ways," said Bob Hutchens, CEO of StemBioSys.
- Thus, these mature human atrial cells mirror those found in a natural, beating heart and should be better predictors of drug effects and toxicity.
- Mr. Hutchens concluded, "CELLvo™ Atrial Cardiomyocyte is the first of several anticipated product launches utilizing our groundbreaking hiPSC technology.
Retrieved on:
Monday, February 13, 2023
United States Air Force Scientific Advisory Board,
Life,
IPSC,
Neuron,
Scripps Research,
Microglia,
Cell,
Doctor of Philosophy,
Culture,
DSM-IV codes,
Olfactory toxicity in fish,
Stem cell,
Astrocyte,
SAN,
Research,
Today,
Drug discovery,
Drug,
Extracellular matrix,
Longevity,
Pharmaceutical industry,
Vaccine SAN ANTONIO, Feb. 13, 2023 /PRNewswire/ -- StemBioSys, Inc. (StemBioSys) announced today the launch of NeuroMatrix™, an astrocyte-derived extracellular matrix that enables the culture of human induced pluripotent stem cell (hiPSC) derived and primary neural cell types. StemBioSys designed NeuroMatrix™ to expand the use of iPSC-derived neurons in drug discovery and toxicity testing.
Key Points:
- SAN ANTONIO, Feb. 13, 2023 /PRNewswire/ -- StemBioSys, Inc. (StemBioSys) announced today the launch of NeuroMatrix™, an astrocyte-derived extracellular matrix that enables the culture of human induced pluripotent stem cell (hiPSC) derived and primary neural cell types.
- "Currently, the use of human pluripotent stem cell-derived neurons is limited by their slow and incomplete maturation and the short longevity of cultures.
- NeuroMatrix™ is an astrocyte-derived extracellular matrix that provides the necessary biochemical and mechanical cues to allow for the differentiation, maturation, and assay of mature neural cell types.
- Mr. Hutchens concluded, "StemBioSys has repeatedly demonstrated that NeuroMatrix™ contains cues necessary to elicit biologically relevant phenotypes in vitro.
Research,
General Health,
Pharmaceutical,
Oncology,
Genetics,
Clinical Trials,
Science,
Engineering,
Cardiology,
Biotechnology,
Stem Cells,
Health,
Manufacturing,
Bio,
Drug development,
Cell,
Booth,
Health,
SBS,
2D,
Therapy,
Â,
Marketing,
3D,
Society,
Multimedia,
Electrophysiology,
Natural scientific research in Canada,
Standard electrode potential,
Research,
CEO,
Scientific Reports,
Tissue,
Calcium,
Technology,
Safety,
Acquisition,
NIH,
CIPA,
Workflow,
B cell,
Extracellular matrix,
Drug discovery,
Nautilus,
Curi,
University,
Pharmaceutical industry,
Medical imaging,
Pulse,
CURI BIO,
STEMBIOSYS, INC. In parallel, Curi Bio announced it will commercialize the technology through its newly announced product: the Nautilus optical mapping system.
Key Points:
- In parallel, Curi Bio announced it will commercialize the technology through its newly announced product: the Nautilus optical mapping system.
- Curi will make the Nautilus system available to pharmaceutical and research customers as a standalone bioscience instrument, compatible with Curi Bios market-leading cloud-based data analytics platforms.
- Curi will also offer service contracts and partnerships leveraging the system for applications in drug discovery, disease modeling, and safety and efficacy screening.
- The Nautilus system enables researchers the ability to condense days of data acquisition and analysis to minutes via an automated workflow.
The research investigated Matrix Plus alongside conventional approaches to hiPSC-CM culture, including the commonly used Matrigel ECM, to determine the efficiency, reproducibility and functionality of the technology.
Key Points:
- The research investigated Matrix Plus alongside conventional approaches to hiPSC-CM culture, including the commonly used Matrigel ECM, to determine the efficiency, reproducibility and functionality of the technology.
- Over the last two years, StemBioSys and Cartox have been working together on an important application of StemBioSys's unique human-derived CELLvo ECM technology, branded as CELLvo Matrix Plus.
- StemBioSys supported this work by developing and characterizing unique formats of the CELLvo Matrix Plus for use in Dr. Herron's work.
- StemBioSys markets its products to the global research community under the CELLvo brand name.
